Lonza signs multi-product agreement with arGEN-X for therapeutic antibodies
Building on a four-year relationship between the two companies
Lonza and arGEN-X, a Netherlands-based developer of differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, have entered into a new, multi-product commercial licensing agreement.
The licence secures long-term access for arGEN-X and its partners to Lonza’s proprietary GS Xceed system for the creation and development of cell lines to be used in the manufacture of biopharmaceuticals.
The new agreement builds upon a four-year relationship between the two companies. Lonza has manufactured two of arGEN-X’s clinical-stage proprietary therapeutic antibodies to date, as well as a third programme starting clinical trials this year.
The GS Xceed system is Lonza’s latest innovation in mammalian protein expression, which is said to offer reduced cell line construction timelines and increased product yields. For products in the early stages of development, the system was designed to help create commercially viable production cell lines for seamless integration into the Lonza process.
